<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancer Manag Res</journal-id><journal-id journal-id-type="iso-abbrev">Cancer Manag Res</journal-id><journal-id journal-id-type="publisher-id">cmar</journal-id><journal-title-group><journal-title>Cancer Management and Research</journal-title></journal-title-group><issn pub-type="epub">1179-1322</issn><publisher><publisher-name>Dove</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">PMC9440662</article-id><article-id pub-id-type="publisher-id">376784</article-id><article-id pub-id-type="doi">10.2147/CMAR.S376784</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Family History of Cancers Increases Risk of Renal Cell Carcinoma in a Chinese Population</article-title><alt-title alt-title-type="running-authors">Xing et al</alt-title><alt-title alt-title-type="running-title">Xing et al</alt-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-7222-1043</contrib-id><name><surname>Xing</surname><given-names>Siwei</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="ft0001" ref-type="author-notes">*</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Ruan</surname><given-names>Xiaohao</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="ft0001" ref-type="author-notes">*</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Huang</surname><given-names>Jingyi</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="ft0001" ref-type="author-notes">*</xref></contrib><contrib contrib-type="author"><name><surname>Yan</surname><given-names>Jiaqi</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Lin</surname><given-names>Wenhao</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Huang</surname><given-names>Jinlun</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Jiacheng</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Huang</surname><given-names>Da</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="an0002" ref-type="corresp"/></contrib><contrib contrib-type="author"><name><surname>Na</surname><given-names>Rong</given-names></name><xref rid="aff0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="an0001" ref-type="corresp"/></contrib><contrib contrib-type="author"><name><surname>Xu</surname><given-names>Danfeng</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><aff id="aff0001"><label>1</label><institution>Department of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine</institution>, <addr-line>Shanghai</addr-line>, <country>People&#x02019;s Republic of China</country></aff><aff id="aff0002"><label>2</label><institution>Division of Urology, Department of Surgery, Queen Mary Hospital, The University of Hong Kong</institution>, <addr-line>Hong Kong</addr-line>, <country>People&#x02019;s Republic of China</country></aff></contrib-group><author-notes><corresp id="an0001">Correspondence: Rong Na, <institution>Division of Urology, Department of Surgery, Queen Mary Hospital, The University of Hong Kong</institution>, <addr-line>102 Pok Fu Lam Road</addr-line>, <addr-line>Hong Kong</addr-line>, <country>People&#x02019;s Republic of China</country>, Email narong.hs@gmail.com</corresp><corresp id="an0002">Da Huang, <institution>Department of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine</institution>, <addr-line>197 Ruijin 2nd Road</addr-line>, <addr-line>Shanghai</addr-line>, <addr-line>200025</addr-line>, <country>People&#x02019;s Republic of China</country>, Email huangdasjtu@gmail.com</corresp><fn id="ft0001"><label>*</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date pub-type="epub"><day>30</day><month>8</month><year>2022</year></pub-date><pub-date pub-type="collection"><year>2022</year></pub-date><volume>14</volume><fpage>2561</fpage><lpage>2568</lpage><history><date date-type="received"><day>01</day><month>6</month><year>2022</year></date><date date-type="accepted"><day>18</day><month>8</month><year>2022</year></date></history><permissions><copyright-statement>&#x000a9; 2022 Xing et al.</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Xing et al.</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/3.0/</ali:license_ref><license-p>This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at <ext-link ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link> and incorporate the Creative Commons Attribution &#x02013; Non Commercial (unported, v3.0) License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (<ext-link ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link>).</license-p></license></permissions><abstract><sec id="s2001"><title>Purpose</title><p>To explore the impact of family history (FH) on renal cell carcinoma (RCC) and its pathological subtype clear cell RCC (ccRCC) in a Chinese population; a significant association has previously been determined not only in familial cancer syndrome but also in sporadic cases in western populations.</p></sec><sec id="s2002"><title>Methods</title><p>Consecutive patients with kidney tumors from October 2017 to May 2021 at a tertiary hospital in Shanghai were enrolled in the study. Demographic and clinical information was collected, including age, gender, FH (positive or negative, types of cancers, degree of relatives, etc.), pathological diagnosis, and Fuhrman grades.</p></sec><sec id="s2003"><title>Results</title><p>A positive FH of any cancer was observed in 26.5% of the RCC patients, while only 16.8% patients with benign kidney tumor were found to have a positive FH. A strong correlation was observed between FH of any cancers in first-degree relatives and RCC (odds ratio [OR]=4.60, 95% confidence interval [CI]: 1.95&#x02013;10.85, <italic toggle="yes">P</italic>=5.50&#x000d7;10<sup>&#x02212;5</sup>) or ccRCC (OR=4.63, 95% CI: 1.95&#x02013;11.02, <italic toggle="yes">P</italic>=9.63&#x000d7;10<sup>&#x02212;5</sup>). In subgroup analysis, FH of digestive cancers was significantly associated with RCC (OR=4.42, 95% CI: 1.35&#x02013;14.51, <italic toggle="yes">P</italic>=0.005) or ccRCC (OR=4.14, 95% CI: 1.25&#x02013;13.75, <italic toggle="yes">P</italic>=6.84&#x000d7;10<sup>&#x02212;4</sup>). Similar results were found in multivariate analyses. However, no significant association was observed between FH and age at onset.</p></sec><sec id="s2004"><title>Conclusion</title><p>FH was an independent risk factor for RCC and ccRCC in this Chinese population. FH of any cancer in first-degree relatives and FH of digestive cancers were found to be the most significant risk factors for kidney cancers.</p></sec></abstract><kwd-group kwd-group-type="author"><title>Keywords</title><kwd>Chinese population</kwd><kwd>family history</kwd><kwd>renal cell carcinoma</kwd><kwd>risk factor</kwd><kwd>multivariate regression analysis</kwd></kwd-group><funding-group><award-group><funding-source>
<institution-wrap><institution>this study has not received any funding resources</institution></institution-wrap>
</funding-source></award-group></funding-group><counts><fig-count count="2"/><table-count count="7"/><ref-count count="32"/><page-count count="8"/></counts></article-meta></front><body><sec sec-type="intro" id="s0001"><title>Introduction</title><p>As the seventh most common malignant carcinoma worldwide, the incidence of kidney cancer has been increasing rapidly over the past few years.<xref rid="cit0001" ref-type="bibr">1</xref> Among the different pathological types, renal cell carcinoma (RCC) may account for over 80% of kidney cancers.<xref rid="cit0002" ref-type="bibr">2</xref> In contrast to the increased exploration of innovative treatment targets and prognostic models, knowledge on the risk factors for and predisposition to the disease has barely evolved.</p><p>Risk factors including age, gender, smoking, and alcohol intake have been found to be correlated with RCC.<xref rid="cit0003" ref-type="bibr">3&#x02013;6</xref> An excess accumulation of adipose tissue, particularly visceral adipose tissue, has also been observed in the development of RCC,<xref rid="cit0007" ref-type="bibr">7&#x02013;9</xref> which makes obesity another general risk factor. Although most cases are sporadically diagnosed, a family history (FH) of cancer should also be considered as a valuable factor, especially since certain genetic mutations in genes such as Von Hippel&#x02013;Lindau (VHL), fumarate hydratase, and succinate dehydrogenase B have established associations with RCC.<xref rid="cit0010" ref-type="bibr">10&#x02013;12</xref></p><p>In addition, a positive FH in relatives of RCC patients may be associated with disease onset and outcome. For example, sequential research from the Swedish public health service found that patients with a positive FH had a 4.58-fold higher risk (95% confidence interval [CI]: 2.87&#x02013;6.94) of RCC and could also suffer from subsequent cancer after the onset of RCC.<xref rid="cit0013" ref-type="bibr">13</xref>,<xref rid="cit0014" ref-type="bibr">14</xref> Studies regarding the association between FH and RCC risk have mostly focused on western populations.<xref rid="cit0004" ref-type="bibr">4</xref>,<xref rid="cit0013" ref-type="bibr">13</xref> Unfortunately, related research based on an eastern population, such as Japanese<xref rid="cit0015" ref-type="bibr">15</xref> or Korean,<xref rid="cit0016" ref-type="bibr">16</xref> focused on genotyping and genetic mutations and did not provide explicit data on patients&#x02019; epidemiological features.</p><p>To our knowledge, no similar study has been published based on a Chinese population to date. This prompted us to explore the association between FH and the clinical onset of RCC and provide evidence for risk evaluation in affected individuals. In the present study, we evaluated the association between FH of different types of kidney cancers at different levels of relatives and the risk of RCC, using a consecutive surgical cohort, in Chinese patients.</p></sec><sec id="s0002"><title>Patients and Methods</title><sec id="s0002-s2001"><title>Study Population and Study Design</title><p>This is a retrospective study based on a group of consecutive patients with kidney tumors undergoing partial or radical surgery from October 2017 to May 2021 at Ruijin Hospital, a tertiary hospital in Shanghai, China. The study was approved by the institutional review board of Shanghai Ruijin Hospital (central IRB no. KY2016-343, 24 Nov 2016, version 03), and written informed consent was obtained from each participant. Patients were excluded from the present study if they were uncertain about either the type of cancer of a positive FH or the overall situation of the FH of cancer.</p><p>A total of 484 cases were finally included in the present study. To ensure data integrity and legitimacy, FH of cancers was collected by investigators through a structured questionnaire (positive or negative, types of cancers, degree of relatives, etc.).</p><p>A first-degree FH was defined as having direct blood relatives with a cancer history. FH of digestive cancers was defined as positive FH of gastric and colonic cancers. Other detailed demographic and clinical information was collected before and after surgery, including age, gender, pathological diagnosis, and Fuhrman grades.</p><p>All surgical specimens were independently examined and graded by two experienced pathologists. Carcinoma of Fuhrman grade 1&#x02013;2 was defined as the low-grade group, while that of Fuhrman grade 3&#x02013;4 was defined as the high-grade group.<xref rid="cit0017" ref-type="bibr">17</xref>,<xref rid="cit0018" ref-type="bibr">18</xref></p></sec><sec id="s0002-s2002"><title>Statistical Analyses</title><p>The chi-squared test or Fisher&#x02019;s exact test was used in univariable analysis for categorical variables. Multivariable logistic regression analysis was conducted to further evaluate the associations. Survival analysis for disease-free survival (age at onset) was evaluated by the log-rank test (Kaplan&#x02013;Meier). A two-tailed <italic toggle="yes">P</italic>&#x0003c;0.05 was considered statistically significant. All statistical analyses were performed using GraphPad Prism (version 6.00 for Windows, GraphPad Software) and SPSS Statistics (IBM Corp., IBM SPSS Statistics for Windows, version 24.0, released 2016).</p></sec></sec><sec id="s0003"><title>Results</title><sec id="s0003-s2001"><title>Demographic Observation Revealed a Higher Co-Morbidity of Positive FH with RCC</title><p>Demographic characteristics and baseline information of the study cohort are shown in <xref rid="t0001" ref-type="table">Table 1</xref>. Among 484 cases, 389 (80.4%) were pathologically diagnosed as RCC, and the rest were diagnosed as benign tumors, such as complicated renal cyst, angiomyolipoma, or oncocytoma. Of the patients with RCC, 311 were diagnosed as clear cell renal cell carcinoma (ccRCC), which accounted for 79.9% of all RCC. Detailed information on the subtypes of RCC is presented in <xref rid="t0002" ref-type="table">Table 2</xref>. The median age of the patients was 57 years (interquartile range [IQR]: 14&#x02013;89 years).<table-wrap position="float" id="t0001"><label>Table 1</label><caption><p>Demographic Characteristics and Baseline Information of the Study Cohort</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="1">Variables</th><th rowspan="2" colspan="1">Total</th><th colspan="2" rowspan="1">RCC</th><th rowspan="2" colspan="1">Non-Carcinoma*</th></tr><tr><th rowspan="1" colspan="1">All RCC</th><th rowspan="1" colspan="1">ccRCC</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Total</td><td rowspan="1" colspan="1">484</td><td rowspan="1" colspan="1">389</td><td rowspan="1" colspan="1">311</td><td rowspan="1" colspan="1">95</td></tr><tr><td rowspan="1" colspan="1">Gender</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;Male, n (%)</td><td rowspan="1" colspan="1">299</td><td rowspan="1" colspan="1">262 (67.4%)</td><td rowspan="1" colspan="1">213 (68.5%)</td><td rowspan="1" colspan="1">37 (38.9%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Female, n (%)</td><td rowspan="1" colspan="1">189</td><td rowspan="1" colspan="1">127 (32.6%)</td><td rowspan="1" colspan="1">98 (31.5%)</td><td rowspan="1" colspan="1">58 (61.1%)</td></tr><tr><td rowspan="1" colspan="1">Age (years), median (IQR)</td><td align="center" rowspan="1" colspan="1">57 (14&#x02013;89)</td><td rowspan="1" colspan="1">58 (25&#x02013;84)</td><td rowspan="1" colspan="1">59 (30&#x02013;84)</td><td rowspan="1" colspan="1">53 (14&#x02013;89)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02265;50, n (%)</td><td rowspan="1" colspan="1">360</td><td rowspan="1" colspan="1">301 (77.4%)</td><td rowspan="1" colspan="1">246 (79.1%)</td><td rowspan="1" colspan="1">59 (62.1%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x0003c;50, n (%)</td><td rowspan="1" colspan="1">124</td><td rowspan="1" colspan="1">88 (22.6%)</td><td rowspan="1" colspan="1">65 (20.9%)</td><td rowspan="1" colspan="1">36 (37.9%)</td></tr><tr><td rowspan="1" colspan="1">FH of any cancer</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;Yes, n (%)</td><td rowspan="1" colspan="1">119</td><td rowspan="1" colspan="1">103 (26.5%)</td><td rowspan="1" colspan="1">81 (26.0%)</td><td rowspan="1" colspan="1">16 (16.8%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;No, n (%)</td><td rowspan="1" colspan="1">365</td><td rowspan="1" colspan="1">286 (73.5%)</td><td rowspan="1" colspan="1">230 (74.0%)</td><td rowspan="1" colspan="1">79 (83.2%)</td></tr><tr><td rowspan="1" colspan="1">Grade (Fuhrman)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;1</td><td rowspan="1" colspan="1">31</td><td rowspan="1" colspan="1">31</td><td rowspan="1" colspan="1">28</td><td rowspan="1" colspan="1">&#x02013;</td></tr><tr><td rowspan="1" colspan="1">&#x02003;2</td><td rowspan="1" colspan="1">240</td><td rowspan="1" colspan="1">240</td><td rowspan="1" colspan="1">212</td><td rowspan="1" colspan="1">&#x02013;</td></tr><tr><td rowspan="1" colspan="1">&#x02003;3</td><td rowspan="1" colspan="1">65</td><td rowspan="1" colspan="1">65</td><td rowspan="1" colspan="1">53</td><td rowspan="1" colspan="1">&#x02013;</td></tr><tr><td rowspan="1" colspan="1">&#x02003;4</td><td rowspan="1" colspan="1">19</td><td rowspan="1" colspan="1">19</td><td rowspan="1" colspan="1">17</td><td rowspan="1" colspan="1">&#x02013;</td></tr></tbody></table><table-wrap-foot><fn id="tfn0001"><p><bold>Note</bold>: *Non-carcinoma: benign pathological diagnosis.</p></fn><fn id="tfn0002"><p><bold>Abbreviations</bold>: RCC, renal cell carcinoma; ccRCC, clear cell renal cell carcinoma; FH, family history.</p></fn></table-wrap-foot></table-wrap>
<table-wrap position="float" id="t0002"><label>Table 2</label><caption><p>Subtype Information of RCC and Benign Pathological Diagnosis</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="2" rowspan="1">RCC</th><th colspan="2" rowspan="1">Benign Pathological Diagnosis</th></tr><tr><th rowspan="1" colspan="1">Diagnosis</th><th rowspan="1" colspan="1">Cases</th><th rowspan="1" colspan="1">Diagnosis</th><th rowspan="1" colspan="1">Cases</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">ccRCC</td><td rowspan="1" colspan="1">311</td><td rowspan="1" colspan="1">Angiomyolipoma</td><td rowspan="1" colspan="1">47</td></tr><tr><td rowspan="1" colspan="1">Papillary RCC (pRCC)</td><td rowspan="1" colspan="1">40</td><td rowspan="1" colspan="1">Complicated cyst</td><td rowspan="1" colspan="1">35</td></tr><tr><td rowspan="1" colspan="1">Unclassifiable RCC</td><td rowspan="1" colspan="1">18</td><td rowspan="1" colspan="1">Oncocytoma</td><td rowspan="1" colspan="1">10</td></tr><tr><td rowspan="1" colspan="1">ccRCC combined with pRCC</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">Lipoma</td><td rowspan="1" colspan="1">2</td></tr><tr><td rowspan="1" colspan="1">Chromophobe RCC</td><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">Metanephric adenoma</td><td rowspan="1" colspan="1">1</td></tr><tr><td rowspan="1" colspan="1">RCC associated with Xp11.2 translocations/TFE3 gene fusions</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Mucinous tubular and spindle cell renal carcinoma</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Leiomyosarcoma</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Sarcomatoid carcinoma</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Biphasic squamoid alveolar RCC</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">RCC with leiomyomatous stroma</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Total</td><td rowspan="1" colspan="1">389</td><td rowspan="1" colspan="1">Total</td><td rowspan="1" colspan="1">95</td></tr></tbody></table><table-wrap-foot><fn id="tfn0003"><p><bold>Abbreviations</bold>: RCC, renal cell carcinoma; ccRCC, clear cell renal cell carcinoma; pRCC, papillary renal cell carcinoma.</p></fn></table-wrap-foot></table-wrap>
</p><p>A positive FH of any cancer was observed in 26.5% of the RCC patients (26.0% of ccRCC), while only 16.8% patients with a benign kidney tumor were found to have a positive FH (<xref rid="t0001" ref-type="table">Table 1</xref>). Further stratification analyses discovered that most of the positive FHs presented in a first-degree relative (98 out of 119, 82.4%). Regarding types of cancers, seven cases of RCC (1.8% positive rate) had a positive FH of RCC, six of whom were ccRCC patients (1.9% positive rate), while none of the patients with a benign kidney tumor had a positive FH of RCC (<xref rid="t0003" ref-type="table">Table 3</xref>). Digestive cancers were established as the most frequent co-morbidity.<table-wrap position="float" id="t0003"><label>Table 3</label><caption><p>Association Between Family History and RCC</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="1">Variables</th><th rowspan="2" colspan="1">Total</th><th colspan="2" rowspan="1">RCC</th><th rowspan="2" colspan="1">Non-Carcinoma (n=95)</th><th colspan="2" rowspan="1">All RCC vs Non-Carcinoma</th><th colspan="2" rowspan="1">ccRCC vs Non-Carcinoma</th></tr><tr><th rowspan="1" colspan="1">All RCC (n=389)</th><th rowspan="1" colspan="1">ccRCC (n=311)</th><th rowspan="1" colspan="1">OR (95% CI)</th><th rowspan="1" colspan="1"><italic toggle="yes">P</italic>-Value</th><th rowspan="1" colspan="1">OR (95% CI)</th><th rowspan="1" colspan="1"><italic toggle="yes">P</italic>-Value</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">FH of any cancers</td><td rowspan="1" colspan="1">119</td><td rowspan="1" colspan="1">103 (26.5%)</td><td rowspan="1" colspan="1">81 (26.1%)</td><td rowspan="1" colspan="1">16 (16.9%)</td><td rowspan="1" colspan="1">1.78 (0.99&#x02013;3.19)</td><td rowspan="1" colspan="1">0.062</td><td rowspan="1" colspan="1">1.74 (0.96&#x02013;3.15)</td><td rowspan="1" colspan="1">0.074</td></tr><tr><td rowspan="1" colspan="1">FH of any cancers in first-degree relatives, n (%)</td><td rowspan="1" colspan="1">98</td><td rowspan="1" colspan="1">92 (23.7%)</td><td rowspan="1" colspan="1">74 (23.8%)</td><td rowspan="1" colspan="1">6 (6.3%)</td><td rowspan="1" colspan="1">4.60 (1.95&#x02013;10.85)</td><td align="center" rowspan="1" colspan="1">5.50&#x000d7;10<sup>&#x02212;5</sup></td><td rowspan="1" colspan="1">4.63 (1.95&#x02013;11.02)</td><td align="center" rowspan="1" colspan="1">9.63&#x000d7;10<sup>&#x02212;5</sup></td></tr><tr><td rowspan="1" colspan="1">FH of cancers in different systems</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;FH of digestive cancers</td><td rowspan="1" colspan="1">52</td><td rowspan="1" colspan="1">49 (12.6%)</td><td rowspan="1" colspan="1">37 (11.9%)</td><td rowspan="1" colspan="1">3 (3.2%)</td><td rowspan="1" colspan="1">4.42 (1.35&#x02013;14.51)</td><td rowspan="1" colspan="1">0.005</td><td rowspan="1" colspan="1">4.14 (1.25&#x02013;13.75)</td><td align="center" rowspan="1" colspan="1">6.84&#x000d7;10<sup>&#x02212;4</sup></td></tr><tr><td rowspan="1" colspan="1">&#x02003;FH of pulmonary cancers</td><td rowspan="1" colspan="1">29</td><td rowspan="1" colspan="1">26 (6.7%)</td><td rowspan="1" colspan="1">21 (6.8%)</td><td rowspan="1" colspan="1">3 (3.2%)</td><td rowspan="1" colspan="1">2.20 (0.65&#x02013;7.42)</td><td rowspan="1" colspan="1">0.24</td><td rowspan="1" colspan="1">2.22 (0.65&#x02013;7.62)</td><td rowspan="1" colspan="1">0.32</td></tr><tr><td rowspan="1" colspan="1">&#x02003;FH of RCC</td><td rowspan="1" colspan="1">7</td><td rowspan="1" colspan="1">7 (1.8%)</td><td rowspan="1" colspan="1">6 (1.9%)</td><td rowspan="1" colspan="1">0 (0.0%)</td><td rowspan="1" colspan="1">2.62 (0.14&#x02013;48.1)</td><td rowspan="1" colspan="1">0.59</td><td rowspan="1" colspan="1">2.84 (0.15&#x02013;53.00)</td><td rowspan="1" colspan="1">0.59</td></tr><tr><td rowspan="1" colspan="1">&#x02003;FH of other cancers</td><td rowspan="1" colspan="1">31</td><td rowspan="1" colspan="1">21 (5.4%)</td><td rowspan="1" colspan="1">17 (5.5%)</td><td rowspan="1" colspan="1">10 (10.5%)</td><td rowspan="1" colspan="1">0.15 (0.05&#x02013;0.47)</td><td rowspan="1" colspan="1">0.001</td><td rowspan="1" colspan="1">0.16 (0.05&#x02013;0.50)</td><td rowspan="1" colspan="1">0.002</td></tr></tbody></table><table-wrap-foot><fn id="tfn0004"><p><bold>Abbreviations</bold>: RCC, renal cell carcinoma; ccRCC, clear cell renal cell carcinoma; FH, family history.</p></fn></table-wrap-foot></table-wrap>
</p></sec><sec id="s0003-s2002"><title>FH Could Be Considered as an Independent Risk Factor for RCC</title><p>We then set out to evaluate the influence of FH on RCC incidence, and notably the most common pathological type, ccRCC.</p><p>FH of any cancers increased the risk of RCC (odds ratio [OR]=1.78, 95% CI: 0.99&#x02013;3.19, <italic toggle="yes">P</italic>=0.062) and ccRCC (OR=1.74, 95% CI: 0.96&#x02013;3.15, <italic toggle="yes">P</italic>=0.074) (<xref rid="t0003" ref-type="table">Table 3</xref>) at marginally significant levels. The percentages of RCC patients and ccRCC patients with a positive FH of any cancer in first-degree relatives were 23.7% (OR=4.60, 95% CI: 1.95&#x02013;10.85, <italic toggle="yes">P</italic>=5.50&#x000d7;10<sup>&#x02212;5</sup>) and 23.8% (OR=4.63, 95% CI: 1.95&#x02013;11.02, <italic toggle="yes">P</italic>=9.63&#x000d7;10<sup>&#x02212;5</sup>), respectively, which were significantly higher than those in patients with benign tumors (6.3%) (<xref rid="t0003" ref-type="table">Table 3</xref>). These results indicate that a positive FH in first-degree relatives may be a risk factor for RCC and ccRCC.</p><p>We then evaluated whether a positive FH of specific types of cancers could be associated with the risk of RCC or ccRCC. We observed that 12.6% of the RCC patients (OR=4.42, 95% CI: 1.35&#x02013;14.51, <italic toggle="yes">P</italic>=0.005) and 11.9% of the ccRCC patients (OR=4.14, 95% CI: 1.25&#x02013;13.75, <italic toggle="yes">P</italic>=6.84&#x000d7;10<sup>&#x02212;4</sup>) had a positive FH of digestive cancers, which was significantly higher than in patients with benign tumors (3.2%) (<xref rid="t0003" ref-type="table">Table 3</xref>). No association was observed between FH of other specific cancer types and RCC or ccRCC.</p><p>To further examine whether FH could be an independent risk factor for RCC, we performed multivariate logistic regression analyses adjusting for gender and age (<xref rid="t0004" ref-type="table">Table 4</xref>). The results suggested that FH of any cancer was independently and significantly associated with RCC (OR=1.85, 95% CI: 1.01&#x02013;3.37, <italic toggle="yes">P</italic>=0.045). This association was even stronger in patients with a positive FH in first-degree relatives (OR=4.36, 95% CI: 1.83&#x02013;10.42, <italic toggle="yes">P</italic>=0.001). In addition, a positive FH of digestive cancers was an independent risk factor for RCC (OR=4.02, 95% CI: 1.21&#x02013;13.36, <italic toggle="yes">P</italic>=0.023). We discovered that their influence was also significant in the sole pathological type ccRCC (<xref rid="t0004" ref-type="table">Table 4</xref>).<table-wrap position="float" id="t0004"><label>Table 4</label><caption><p>Multivariate Logistic Regression Analyses Evaluating the Association Between FH and RCC</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="1">Variables</th><th colspan="2" rowspan="1">RCC vs Non-Carcinoma</th><th colspan="2" rowspan="1">ccRCC vs Non-Carcinoma</th><th colspan="2" rowspan="1">Low Grade (1&#x02013;2) vs High Grade (3&#x02013;4)</th></tr><tr><th rowspan="1" colspan="1">OR (95% CI)</th><th rowspan="1" colspan="1"><italic toggle="yes">P</italic>-Value</th><th rowspan="1" colspan="1">OR (95% CI)</th><th rowspan="1" colspan="1"><italic toggle="yes">P</italic>-Value</th><th rowspan="1" colspan="1">OR (95% CI)</th><th rowspan="1" colspan="1"><italic toggle="yes">P</italic>-value</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Gender</td><td rowspan="1" colspan="1">3.34 (2.09&#x02013;5.32)</td><td rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1">3.48 (2.14&#x02013;5.66)</td><td rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1">2.25 (1.23&#x02013;4.13)</td><td rowspan="1" colspan="1">0.009</td></tr><tr><td rowspan="1" colspan="1">Age (&#x02265;50 years)</td><td rowspan="1" colspan="1">2.08 (1.27&#x02013;3.40)</td><td rowspan="1" colspan="1">0.003</td><td rowspan="1" colspan="1">2.38 (1.41&#x02013;4.00)</td><td rowspan="1" colspan="1">0.001</td><td rowspan="1" colspan="1">3.72 (1.63&#x02013;8.50)</td><td rowspan="1" colspan="1">0.002</td></tr><tr><td rowspan="1" colspan="1">FH of any cancers*</td><td rowspan="1" colspan="1">1.85 (1.01&#x02013;3.37)</td><td rowspan="1" colspan="1">0.045</td><td rowspan="1" colspan="1">1.90 (1.03&#x02013;3.53)</td><td rowspan="1" colspan="1">0.041</td><td rowspan="1" colspan="1">0.73 (0.40&#x02013;1.35)</td><td rowspan="1" colspan="1">0.314</td></tr><tr><td rowspan="1" colspan="1">FH of any cancers in first-degree relatives*</td><td rowspan="1" colspan="1">4.36 (1.83&#x02013;10.42)</td><td rowspan="1" colspan="1">0.001</td><td rowspan="1" colspan="1">4.76 (1.96&#x02013;11.52)</td><td rowspan="1" colspan="1">0.001</td><td rowspan="1" colspan="1">0.79 (0.42&#x02013;1.45)</td><td rowspan="1" colspan="1">0.441</td></tr><tr><td rowspan="1" colspan="1">FH of digestive cancers*</td><td rowspan="1" colspan="1">4.02 (1.21&#x02013;13.36)</td><td rowspan="1" colspan="1">0.023</td><td rowspan="1" colspan="1">3.69 (1.10&#x02013;12.43)</td><td rowspan="1" colspan="1">0.035</td><td rowspan="1" colspan="1">0.77 (0.35&#x02013;1.71)</td><td rowspan="1" colspan="1">0.522</td></tr></tbody></table><table-wrap-foot><fn id="tfn0005"><p><bold>Note</bold>: *Adjusted for gender and age category.</p></fn><fn id="tfn0006"><p><bold>Abbreviations</bold>: FH, family history; RCC, renal cell carcinoma.</p></fn></table-wrap-foot></table-wrap>
</p></sec><sec id="s0003-s2003"><title>FH Did Not Share an Association with Age at Onset or Pathological Grading</title><p>Next, we investigated whether FH could also serve as a prognostic indicator. We employed the following two common factors for assessment: pathological grading and age at onset of the disease.</p><p>We performed multivariate logistic regression analysis to evaluate the influence of FH on prediction of pathological grades. However, after adjustment for gender and age, no significant association was observed between FH and high Fuhrman grade (grade 3&#x02013;4) of RCC (<xref rid="t0004" ref-type="table">Table 4</xref>).</p><p>We then analyzed the association between FH and age at onset. No significant association was found between early age at onset (&#x0003c;50 years), a potential indicator of poorer prognosis, and FH (all <italic toggle="yes">P</italic>&#x0003e;0.05) (<xref rid="t0005" ref-type="table">Table 5</xref>) through Kaplan&#x02013;Meier analyses. Moreover, survival analyses did not find any significant link between FH and age at onset (all <italic toggle="yes">P</italic>&#x0003e;0.05) (<xref rid="f0001" ref-type="fig">Figure 1A&#x02013;F</xref>).<table-wrap position="float" id="t0005"><label>Table 5</label><caption><p>Association Between FH and Age at Onset</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="1">Age (Years)</th><th rowspan="2" colspan="1">Total</th><th colspan="2" rowspan="1">FH</th><th colspan="2" rowspan="1">FH in First-Degree Relatives</th><th colspan="2" rowspan="1">FH of Digestive Cancers</th></tr><tr><th rowspan="1" colspan="1">Positive</th><th rowspan="1" colspan="1">Negative</th><th rowspan="1" colspan="1">Positive</th><th rowspan="1" colspan="1">Negative</th><th rowspan="1" colspan="1">Positive</th><th rowspan="1" colspan="1">Negative</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">RCC patients</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02265;50, n (%)</td><td rowspan="1" colspan="1">301</td><td rowspan="1" colspan="1">73 (70.9%)</td><td rowspan="1" colspan="1">228 (79.7%)</td><td rowspan="1" colspan="1">72 (78.3%)</td><td rowspan="1" colspan="1">229 (77.1%)</td><td rowspan="1" colspan="1">36 (76.6%)</td><td rowspan="1" colspan="1">263 (77.4%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x0003c;50, n (%)</td><td rowspan="1" colspan="1">88</td><td rowspan="1" colspan="1">30 (29.1%)</td><td rowspan="1" colspan="1">58 (20.3%)</td><td rowspan="1" colspan="1">20 (21.7%)</td><td rowspan="1" colspan="1">68 (22.9%)</td><td rowspan="1" colspan="1">11 (23.4%)</td><td rowspan="1" colspan="1">77 (22.6%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;<italic toggle="yes">P</italic>-value</td><td rowspan="1" colspan="1"/><td colspan="2" rowspan="1">0.075</td><td colspan="2" rowspan="1">0.89</td><td colspan="2" rowspan="1">0.86</td></tr><tr><td rowspan="1" colspan="1">ccRCC patients</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02265;50, n (%)</td><td rowspan="1" colspan="1">246</td><td rowspan="1" colspan="1">58 (71.6%)</td><td rowspan="1" colspan="1">188 (81.7%)</td><td rowspan="1" colspan="1">57 (77.0%)</td><td rowspan="1" colspan="1">189 (79.7%)</td><td rowspan="1" colspan="1">29 (78.4%)</td><td rowspan="1" colspan="1">217 (79.2%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x0003c;50, n (%)</td><td rowspan="1" colspan="1">65</td><td rowspan="1" colspan="1">23 (28.4%)</td><td rowspan="1" colspan="1">42 (18.3%)</td><td rowspan="1" colspan="1">17 (23.0%)</td><td rowspan="1" colspan="1">48 (20.3%)</td><td rowspan="1" colspan="1">8 (21.6%)</td><td rowspan="1" colspan="1">57 (20.8%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;<italic toggle="yes">P</italic>-value</td><td rowspan="1" colspan="1"/><td colspan="2" rowspan="1">0.058</td><td colspan="2" rowspan="1">0.63</td><td colspan="2" rowspan="1">1.00</td></tr></tbody></table><table-wrap-foot><fn id="tfn0007"><p><bold>Abbreviations</bold>: FH, family history; RCC, renal cell carcinoma, ccRCC, clear cell renal cell carcinoma.</p></fn></table-wrap-foot></table-wrap>
<fig position="float" id="f0001" fig-type="figure"><label>Figure 1</label><caption><p>Results of Kaplan&#x02013;Meier survival analyses: (<bold>A</bold>) association between FH of all cancer and age at onset of RCC; (<bold>B</bold>) association between FH in first-degree relatives and age at onset of RCC; (<bold>C</bold>) association between FH of digestive cancer and age at onset of RCC; (<bold>D</bold>) association between FH of all cancer and age at onset of ccRCC; (<bold>E</bold>) association between FH in first-degree relatives and age at onset of ccRCC; (<bold>F</bold>) association between FH of digestive cancer and age at onset of ccRCC. <italic toggle="yes">P</italic>-values obtained by log-rank test. HR obtained by log-rank test, with 95% CI in parentheses.</p></caption><graphic xlink:href="CMAR-14-2561-g0001" content-type="print-only" position="float"/><attrib><bold>Abbreviations</bold>: FH, family history; RCC, renal cell carcinoma; ccRCC, clear cell renal cell carcinoma; HR, hazard ratio; CI, confidence interval.</attrib></fig></p></sec></sec><sec id="s0004"><title>Discussion</title><p>This is the first time that the association between FH and RCC has been evaluated in a Chinese population. We found that:<xref rid="cit0001" ref-type="bibr">1</xref> FH of any cancers was a risk factor for RCC and ccRCC;<xref rid="cit0002" ref-type="bibr">2</xref> FH of any cancers in first-degree relatives and FH of digestive cancers were stronger risk factors for RCC and ccRCC;<xref rid="cit0003" ref-type="bibr">3</xref> and FH was not associated with pathological grade (Fuhrman grade) or age at onset (early onset). Significant correlations are summarized and visualized in <xref rid="f0002" ref-type="fig">Figure 2</xref>.<fig position="float" id="f0002" fig-type="figure"><label>Figure 2</label><caption><p>Graphic presenting significant correlations between FH and RCC. FH of any cancers in first-degree relatives and FH of digestive cancers are considered as risk factors for RCC.</p></caption><graphic xlink:href="CMAR-14-2561-g0002" content-type="print-only" position="float"/><attrib><bold>Abbreviations</bold>: FH, family history; RCC, renal cell carcinoma; OR, odds ratio; CI, confidence interval.</attrib></fig></p><p>Our findings are consistent with those of previously published results from other countries in people of other ethnicities.<xref rid="cit0004" ref-type="bibr">4</xref>,<xref rid="cit0013" ref-type="bibr">13</xref>,<xref rid="cit0016" ref-type="bibr">16</xref> However, the importance of positive FH in patients with renal tumors has not yet been discussed thoroughly. Most of the related literature focused on hereditary patterns of RCC types, such as VHL disease,<xref rid="cit0019" ref-type="bibr">19</xref> hereditary papillary RCC,<xref rid="cit0011" ref-type="bibr">11</xref> and hereditary leiomyomatosis.<xref rid="cit0016" ref-type="bibr">16</xref>,<xref rid="cit0020" ref-type="bibr">20</xref> In our study, we did not come across many familial cases of RCC, although all positive FHs of RCC were found in patients with malignant renal tumors. Instead, we established that FH is an independent risk factor for RCC.</p><p>Unlike for other cancers, a positive FH did not have an influence on age at onset. For example, a positive FH of prostate cancer (PCa) or BRCA&#x02010;related cancers was related to an earlier age at onset of PCa.<xref rid="cit0021" ref-type="bibr">21</xref> Besides, FH of colorectal cancer (CRC) was also considered to be associated with early-onset CRC (age &#x0003c;50 years).<xref rid="cit0022" ref-type="bibr">22</xref> The unusual discovery in this study of RCC has not been reported in any other epidemiological research, to our knowledge.</p><p>The positive association of first-grade-relative FH with RCC was easy to interpret considering that genetic or epigenetic modifications are more likely to be passed on to the patient. We also observed that most of the FH (~90%) was in first-degree relatives. This could be due to the family planning (one-child) policy in China in the past decades that limited the size of the family.<xref rid="cit0023" ref-type="bibr">23</xref> This could lead to a lack of second-degree relatives. Another possible reason could be the poor medical infrastructure, absence of disease registration, and insufficient vital statistics before the 2000s,<xref rid="cit0024" ref-type="bibr">24</xref> which made it difficult for people and medical workers to capture information on FH (people died without the exact reason being known).</p><p>Our results also showed FH of digestive cancers to be a significant risk factor for RCC in this Chinese population. Several reviews mentioned an observational link between gastrointestinal stromal tumor and onset of RCC, indicating the potential predisposition syndromes and advocating clinical phenotyping and characterization of genotypic features.<xref rid="cit0025" ref-type="bibr">25</xref>,<xref rid="cit0026" ref-type="bibr">26</xref> Familial digestive cancers are likely to be related to Lynch syndrome, sharing a close link with malfunction of mismatch repair (MMR) genes in the DNA repair process.<xref rid="cit0027" ref-type="bibr">27&#x02013;29</xref> Evidence also showed that expression of MMR genes was downregulated in RCC<xref rid="cit0030" ref-type="bibr">30</xref> and specific gene expression was related only in ccRCC.<xref rid="cit0031" ref-type="bibr">31</xref> However, whether MMR gene mutations are associated with RCC in the Chinese population is still unknown, and is worthy of further investigation given the relatively high incidence of digestive cancers in China. Another speculation could arise from the fact that obesity, and specifically the accumulation of adipose tissue in individuals, is considered a risk factor for both RCC and CRC,<xref rid="cit0009" ref-type="bibr">9</xref>,<xref rid="cit0032" ref-type="bibr">32</xref> and investigations at a molecular level may be required to confirm this.</p><p>Our study has several limitations. First, as this was a single-center retrospective study, our results may not represent the entire Chinese population. However, as this center is a tertiary hospital in Shanghai, people from all over the country come here to seek its services. Secondly, the number of cases was relatively small in the present study, because we only included cases with a concrete demographic FH, which was collected through clinical interview. This may have introduced an inevitable bias of omission and also resulted in a limited statistical power to observe some potential differences, for instance, the relationship between FH and age at onset. Nevertheless, our study provides the first evidence on this topic based on a Chinese population. Further research in a larger population and necessary improvement of the study design, such as confirmation of the FH by histopathological examination, may help to advance and augment the findings of our study.</p></sec></body><back><ack><title>Acknowledgments</title><p>This work was supported by grants from the National Natural Science Foundation of China (81772741, 81972405, and 81972645), Shanghai Youth Talent Support Program, and the Shanghai Sailing Program (22YF1440500).</p></ack><sec id="s0005"><title>Abbreviations</title><p>FH, family history; RCC, renal cell carcinoma; ccRCC, clear cell renal cell carcinoma; OR, odds ratio; CI, confidence interval; IQR, interquartile rage; MMR, mismatch repair; IRB, institutional review board.</p></sec><sec id="s0006"><title>Data Sharing Statement</title><p>The data and materials generated and analyzed during the current study are available from Dr. Rong Na on reasonable request.</p></sec><sec id="s0007"><title>Ethics Approval</title><p>The research was carried out according to the principles set out in the Declaration of Helsinki 1964 and all subsequent revisions, and the relevant institutional review board (IRB) at Ruijin Hospital approved the study.</p></sec><sec id="s0008"><title>Consent to Participate</title><p>Informed consent was obtained from all individual participants included in the study.</p></sec><sec id="s0009"><title>Consent for Publication</title><p>The patients or parent/guardian/next of kin (in the case of minors or deceased patients) provided written informed consent for the publication of any data and/or accompanying images.</p></sec><sec sec-type="COI-statement" id="s0010"><title>Disclosure</title><p>The authors have no relevant financial or non-financial interests to disclose.</p></sec><ref-list><title>References</title><ref id="cit0001"><label>1.</label><mixed-citation publication-type="journal"><string-name><surname>Bray</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Ferlay</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Soerjomataram</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Siegel</surname>
<given-names>RL</given-names></string-name>, <string-name><surname>Torre</surname>
<given-names>LA</given-names></string-name>, <string-name><surname>Jemal</surname>
<given-names>A</given-names></string-name>. <article-title>Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title>. <source><italic toggle="yes">CA Cancer J Clin</italic></source>. <year>2018</year>;<volume>68</volume>:<fpage>394</fpage>&#x02013;<lpage>424</lpage>. doi:<pub-id pub-id-type="doi">10.3322/caac.21492</pub-id><pub-id pub-id-type="pmid">30207593</pub-id></mixed-citation></ref><ref id="cit0002"><label>2.</label><mixed-citation publication-type="journal"><string-name><surname>Motzer</surname>
<given-names>RJ</given-names></string-name>, <string-name><surname>Jonasch</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Agarwal</surname>
<given-names>N</given-names></string-name>, et al. <article-title>Kidney cancer, version 2.2017, NCCN clinical practice guidelines in oncology</article-title>. <source><italic toggle="yes">J Natl Compr Canc Netw</italic></source>. <year>2017</year>;<volume>15</volume>:<fpage>804</fpage>&#x02013;<lpage>834</lpage>. doi:<pub-id pub-id-type="doi">10.6004/jnccn.2017.0100</pub-id><pub-id pub-id-type="pmid">28596261</pub-id></mixed-citation></ref><ref id="cit0003"><label>3.</label><mixed-citation publication-type="journal"><string-name><surname>Padala</surname>
<given-names>SA</given-names></string-name>, <string-name><surname>Barsouk</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Thandra</surname>
<given-names>KC</given-names></string-name>, et al. <article-title>Epidemiology of renal cell carcinoma</article-title>. <source><italic toggle="yes">World J Oncol</italic></source>. <year>2020</year>;<volume>11</volume>:<fpage>79</fpage>&#x02013;<lpage>87</lpage>. doi:<pub-id pub-id-type="doi">10.14740/wjon1279</pub-id><pub-id pub-id-type="pmid">32494314</pub-id></mixed-citation></ref><ref id="cit0004"><label>4.</label><mixed-citation publication-type="journal"><string-name><surname>Christensen</surname>
<given-names>MB</given-names></string-name>, <string-name><surname>Wadt</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Jensen</surname>
<given-names>UB</given-names></string-name>, et al. <article-title>Exploring the hereditary background of renal cancer in Denmark</article-title>. <source><italic toggle="yes">PLoS One</italic></source>. <year>2019</year>;<volume>14</volume>:<fpage>e0215725</fpage>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0215725</pub-id><pub-id pub-id-type="pmid">31034483</pub-id></mixed-citation></ref><ref id="cit0005"><label>5.</label><mixed-citation publication-type="journal"><string-name><surname>Gansler</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Fedewa</surname>
<given-names>SA</given-names></string-name>, <string-name><surname>Flanders</surname>
<given-names>WD</given-names></string-name>, <string-name><surname>Pollack</surname>
<given-names>LA</given-names></string-name>, <string-name><surname>Siegel</surname>
<given-names>DA</given-names></string-name>, <string-name><surname>Jemal</surname>
<given-names>A</given-names></string-name>. <article-title>Prevalence of cigarette smoking among patients with different histologic types of kidney cancer</article-title>. <source><italic toggle="yes">Cancer Epidemiol Biomarkers Prev</italic></source>. <year>2020</year>;<volume>29</volume>:<fpage>1406</fpage>&#x02013;<lpage>1412</lpage>. doi:<pub-id pub-id-type="doi">10.1158/1055-9965.EPI-20-0015</pub-id><pub-id pub-id-type="pmid">32357956</pub-id></mixed-citation></ref><ref id="cit0006"><label>6.</label><mixed-citation publication-type="journal"><string-name><surname>Washio</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Mori</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Mikami</surname>
<given-names>K</given-names></string-name>, et al. <article-title>Risk factors for renal cell carcinoma in a Japanese population</article-title>. <source><italic toggle="yes">Asian Pac J Cancer Prev</italic></source>. <year>2014</year>;<volume>15</volume>:<fpage>9065</fpage>&#x02013;<lpage>9070</lpage>. doi:<pub-id pub-id-type="doi">10.7314/APJCP.2014.15.21.9065</pub-id><pub-id pub-id-type="pmid">25422180</pub-id></mixed-citation></ref><ref id="cit0007"><label>7.</label><mixed-citation publication-type="journal"><string-name><surname>Greco</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Cirimele</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Mallio</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Zobel</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Grasso</surname>
<given-names>R</given-names></string-name>. <article-title>Increased visceral adipose tissue in male patients with clear cell renal cell carcinoma</article-title>. <source><italic toggle="yes">Clin Cancer Investig J</italic></source>. <year>2018</year>;<volume>7</volume>(<issue>4</issue>):<fpage>132</fpage>. doi:<pub-id pub-id-type="doi">10.4103/ccij.ccij_62_18</pub-id></mixed-citation></ref><ref id="cit0008"><label>8.</label><mixed-citation publication-type="journal"><string-name><surname>Greco</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Mallio</surname>
<given-names>CA</given-names></string-name>, <string-name><surname>Grippo</surname>
<given-names>R</given-names></string-name>, et al. <article-title>Increased visceral adipose tissue in male patients with non-clear cell renal cell carcinoma</article-title>. <source><italic toggle="yes">Radiol Med</italic></source>. <year>2020</year>;<volume>125</volume>:<fpage>538</fpage>&#x02013;<lpage>543</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s11547-020-01146-6</pub-id><pub-id pub-id-type="pmid">32067162</pub-id></mixed-citation></ref><ref id="cit0009"><label>9.</label><mixed-citation publication-type="journal"><string-name><surname>Greco</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Quarta</surname>
<given-names>LG</given-names></string-name>, <string-name><surname>Grasso</surname>
<given-names>RF</given-names></string-name>, <string-name><surname>Beomonte Zobel</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Mallio</surname>
<given-names>CA</given-names></string-name>. <article-title>Increased visceral adipose tissue in clear cell renal cell carcinoma with and without peritumoral collateral vessels</article-title>. <source><italic toggle="yes">Br J Radiol</italic></source>. <year>2020</year>;<volume>93</volume>:<fpage>20200334</fpage>. doi:<pub-id pub-id-type="doi">10.1259/bjr.20200334</pub-id><pub-id pub-id-type="pmid">32516557</pub-id></mixed-citation></ref><ref id="cit0010"><label>10.</label><mixed-citation publication-type="journal"><string-name><surname>Gossage</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Eisen</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Maher</surname>
<given-names>ER</given-names></string-name>. <article-title>VHL, the story of a tumour suppressor gene</article-title>. <source><italic toggle="yes">Nat Rev Cancer</italic></source>. <year>2015</year>;<volume>15</volume>(<issue>1</issue>):<fpage>55</fpage>&#x02013;<lpage>64</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nrc3844</pub-id><pub-id pub-id-type="pmid">25533676</pub-id></mixed-citation></ref><ref id="cit0011"><label>11.</label><mixed-citation publication-type="journal"><string-name><surname>Verine</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Pluvinage</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Bousquet</surname>
<given-names>G</given-names></string-name>, et al. <article-title>Hereditary renal cancer syndromes: an update of a systematic review</article-title>. <source><italic toggle="yes">Eur Urol</italic></source>. <year>2010</year>;<volume>58</volume>:<fpage>701</fpage>&#x02013;<lpage>710</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.eururo.2010.08.031</pub-id><pub-id pub-id-type="pmid">20817385</pub-id></mixed-citation></ref><ref id="cit0012"><label>12.</label><mixed-citation publication-type="journal"><string-name><surname>Woodward</surname>
<given-names>ER</given-names></string-name>, <string-name><surname>Ricketts</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Killick</surname>
<given-names>P</given-names></string-name>, et al. <article-title>Familial non-VHL clear cell (conventional) renal cell carcinoma: clinical features, segregation analysis, and mutation analysis of FLCN</article-title>. <source><italic toggle="yes">Clin Cancer Res</italic></source>. <year>2008</year>;<volume>14</volume>:<fpage>5925</fpage>&#x02013;<lpage>5930</lpage>. doi:<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-08-0608</pub-id><pub-id pub-id-type="pmid">18794106</pub-id></mixed-citation></ref><ref id="cit0013"><label>13.</label><mixed-citation publication-type="journal"><string-name><surname>Hemminki</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>X</given-names></string-name>. <article-title>Age-specific familial risks for renal cell carcinoma with evidence on recessive heritable effects</article-title>. <source><italic toggle="yes">Kidney Int</italic></source>. <year>2004</year>;<volume>65</volume>:<fpage>2298</fpage>&#x02013;<lpage>2302</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1523-1755.2004.00650.x</pub-id><pub-id pub-id-type="pmid">15149343</pub-id></mixed-citation></ref><ref id="cit0014"><label>14.</label><mixed-citation publication-type="journal"><string-name><surname>Chen</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Fallah</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Sundquist</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Liu</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Hemminki</surname>
<given-names>K</given-names></string-name>. <article-title>Risk of subsequent cancers in renal cell carcinoma survivors with a family history</article-title>. <source><italic toggle="yes">Eur J Cancer</italic></source>. <year>2014</year>;<volume>50</volume>:<fpage>2108</fpage>&#x02013;<lpage>2118</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ejca.2014.05.003</pub-id><pub-id pub-id-type="pmid">24923229</pub-id></mixed-citation></ref><ref id="cit0015"><label>15.</label><mixed-citation publication-type="journal"><string-name><surname>Furuya</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Yao</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Tanaka</surname>
<given-names>R</given-names></string-name>, et al. <article-title>Genetic, epidemiologic and clinicopathologic studies of Japanese Asian patients with Birt-Hogg-Dube syndrome</article-title>. <source><italic toggle="yes">Clin Genet</italic></source>. <year>2016</year>;<volume>90</volume>:<fpage>403</fpage>&#x02013;<lpage>412</lpage>. doi:<pub-id pub-id-type="doi">10.1111/cge.12807</pub-id><pub-id pub-id-type="pmid">27220747</pub-id></mixed-citation></ref><ref id="cit0016"><label>16.</label><mixed-citation publication-type="journal"><string-name><surname>Seo</surname>
<given-names>JY</given-names></string-name>, <string-name><surname>Ahn</surname>
<given-names>JY</given-names></string-name>, <string-name><surname>Keam</surname>
<given-names>B</given-names></string-name>, et al. <article-title>Genotypic and phenotypic characteristics of hereditary leiomyomatosis and renal cell cancer syndrome in Korean patients</article-title>. <source><italic toggle="yes">Ann Lab Med</italic></source>. <year>2021</year>;<volume>41</volume>:<fpage>207</fpage>&#x02013;<lpage>213</lpage>. doi:<pub-id pub-id-type="doi">10.3343/alm.2021.41.2.207</pub-id><pub-id pub-id-type="pmid">33063682</pub-id></mixed-citation></ref><ref id="cit0017"><label>17.</label><mixed-citation publication-type="journal"><string-name><surname>Delahunt</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Eble</surname>
<given-names>JN</given-names></string-name>, <string-name><surname>Egevad</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Samaratunga</surname>
<given-names>H</given-names></string-name>. <article-title>Grading of renal cell carcinoma</article-title>. <source><italic toggle="yes">Histopathology</italic></source>. <year>2019</year>;<volume>74</volume>:<fpage>4</fpage>&#x02013;<lpage>17</lpage>. doi:<pub-id pub-id-type="doi">10.1111/his.13735</pub-id><pub-id pub-id-type="pmid">30565310</pub-id></mixed-citation></ref><ref id="cit0018"><label>18.</label><mixed-citation publication-type="journal"><string-name><surname>Becker</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Hickmann</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Hansen</surname>
<given-names>J</given-names></string-name>, et al. <article-title>Critical analysis of a simplified Fuhrman grading scheme for prediction of cancer specific mortality in patients with clear cell renal cell carcinoma&#x02013;Impact on prognosis</article-title>. <source><italic toggle="yes">Eur J Surg Oncol</italic></source>. <year>2016</year>;<volume>42</volume>:<fpage>419</fpage>&#x02013;<lpage>425</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ejso.2015.09.023</pub-id><pub-id pub-id-type="pmid">26520403</pub-id></mixed-citation></ref><ref id="cit0019"><label>19.</label><mixed-citation publication-type="journal"><string-name><surname>Patel</surname>
<given-names>PH</given-names></string-name>, <string-name><surname>Chadalavada</surname>
<given-names>RS</given-names></string-name>, <string-name><surname>Chaganti</surname>
<given-names>RS</given-names></string-name>, <string-name><surname>Motzer</surname>
<given-names>RJ</given-names></string-name>. <article-title>Targeting von Hippel-Lindau pathway in renal cell carcinoma</article-title>. <source><italic toggle="yes">Clin Cancer Res</italic></source>. <year>2006</year>;<volume>12</volume>:<fpage>7215</fpage>&#x02013;<lpage>7220</lpage>. doi:<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-06-2254</pub-id><pub-id pub-id-type="pmid">17189392</pub-id></mixed-citation></ref><ref id="cit0020"><label>20.</label><mixed-citation publication-type="journal"><string-name><surname>Forde</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Lim</surname>
<given-names>DHK</given-names></string-name>, <string-name><surname>Alwan</surname>
<given-names>Y</given-names></string-name>, et al. <article-title>Hereditary leiomyomatosis and renal cell cancer: clinical, molecular, and screening features in a cohort of 185 affected individuals</article-title>. <source><italic toggle="yes">Eur Urol Oncol</italic></source>. <year>2020</year>;<volume>3</volume>:<fpage>764</fpage>&#x02013;<lpage>772</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.euo.2019.11.002</pub-id><pub-id pub-id-type="pmid">31831373</pub-id></mixed-citation></ref><ref id="cit0021"><label>21.</label><mixed-citation publication-type="journal"><string-name><surname>Xu</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Huang</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Wu</surname>
<given-names>Y</given-names></string-name>, et al. <article-title>Family history is significantly associated with prostate cancer and its early onset in Chinese population</article-title>. <source><italic toggle="yes">Prostate</italic></source>. <year>2019</year>;<volume>79</volume>:<fpage>1762</fpage>&#x02013;<lpage>1766</lpage>. doi:<pub-id pub-id-type="doi">10.1002/pros.23900</pub-id><pub-id pub-id-type="pmid">31497879</pub-id></mixed-citation></ref><ref id="cit0022"><label>22.</label><mixed-citation publication-type="journal"><string-name><surname>Gausman</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Dornblaser</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Anand</surname>
<given-names>S</given-names></string-name>, et al. <article-title>Risk factors associated with early-onset colorectal cancer</article-title>. <source><italic toggle="yes">Clin Gastroenterol Hepatol</italic></source>. <year>2020</year>;<volume>18</volume>:<fpage>2752</fpage>&#x02013;<lpage>9 e2</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.cgh.2019.10.009</pub-id><pub-id pub-id-type="pmid">31622737</pub-id></mixed-citation></ref><ref id="cit0023"><label>23.</label><mixed-citation publication-type="journal"><string-name><surname>Gietel-Basten</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Han</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Cheng</surname>
<given-names>Y</given-names></string-name>. <article-title>Assessing the impact of the &#x0201c;one-child policy&#x0201d; in China: a synthetic control approach</article-title>. <source><italic toggle="yes">PLoS One</italic></source>. <year>2019</year>;<volume>14</volume>:<fpage>e0220170</fpage>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0220170</pub-id><pub-id pub-id-type="pmid">31693666</pub-id></mixed-citation></ref><ref id="cit0024"><label>24.</label><mixed-citation publication-type="journal"><string-name><surname>Wei</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Zeng</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Zheng</surname>
<given-names>R</given-names></string-name>, et al. <article-title>Cancer registration in China and its role in cancer prevention and control</article-title>. <source><italic toggle="yes">Lancet Oncol</italic></source>. <year>2020</year>;<volume>21</volume>:<fpage>e342</fpage>&#x02013;<lpage>e9</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S1470-2045(20)30073-5</pub-id><pub-id pub-id-type="pmid">32615118</pub-id></mixed-citation></ref><ref id="cit0025"><label>25.</label><mixed-citation publication-type="journal"><string-name><surname>Przybycin</surname>
<given-names>CG</given-names></string-name>, <string-name><surname>Magi-Galluzzi</surname>
<given-names>C</given-names></string-name>, <string-name><surname>McKenney</surname>
<given-names>JK</given-names></string-name>. <article-title>Hereditary syndromes with associated renal neoplasia: a practical guide to histologic recognition in renal tumor resection specimens</article-title>. <source><italic toggle="yes">Adv Anat Pathol</italic></source>. <year>2013</year>;<volume>20</volume>:<fpage>245</fpage>&#x02013;<lpage>263</lpage>. doi:<pub-id pub-id-type="doi">10.1097/PAP.0b013e318299b7c6</pub-id><pub-id pub-id-type="pmid">23752087</pub-id></mixed-citation></ref><ref id="cit0026"><label>26.</label><mixed-citation publication-type="journal"><string-name><surname>Agaimy</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Hartmann</surname>
<given-names>A</given-names></string-name>. <article-title>Uncovering hereditary tumor syndromes: emerging role of surgical pathology</article-title>. <source><italic toggle="yes">Semin Diagn Pathol</italic></source>. <year>2018</year>;<volume>35</volume>:<fpage>154</fpage>&#x02013;<lpage>160</lpage>. doi:<pub-id pub-id-type="doi">10.1053/j.semdp.2018.01.001</pub-id><pub-id pub-id-type="pmid">29395463</pub-id></mixed-citation></ref><ref id="cit0027"><label>27.</label><mixed-citation publication-type="journal"><string-name><surname>Sinicrope</surname>
<given-names>FA</given-names></string-name>. <article-title>Lynch syndrome-associated colorectal cancer</article-title>. <source><italic toggle="yes">N Engl J Med</italic></source>. <year>2018</year>;<volume>379</volume>:<fpage>764</fpage>&#x02013;<lpage>773</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMcp1714533</pub-id><pub-id pub-id-type="pmid">30134129</pub-id></mixed-citation></ref><ref id="cit0028"><label>28.</label><mixed-citation publication-type="journal"><string-name><surname>Biller</surname>
<given-names>LH</given-names></string-name>, <string-name><surname>Syngal</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Yurgelun</surname>
<given-names>MB</given-names></string-name>. <article-title>Recent advances in Lynch syndrome</article-title>. <source><italic toggle="yes">Fam Cancer</italic></source>. <year>2019</year>;<volume>18</volume>:<fpage>211</fpage>&#x02013;<lpage>219</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s10689-018-00117-1</pub-id><pub-id pub-id-type="pmid">30627969</pub-id></mixed-citation></ref><ref id="cit0029"><label>29.</label><mixed-citation publication-type="journal"><string-name><surname>Pellat</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Netter</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Perkins</surname>
<given-names>G</given-names></string-name>, et al. &#x000a0;Syndrome de Lynch&#x000a0;: quoi de neuf? <article-title>[Lynch syndrome: what is new?]</article-title>. <source><italic toggle="yes">Bull Cancer</italic></source>. <year>2019</year>;<volume>106</volume>:<fpage>647</fpage>&#x02013;<lpage>655</lpage>. <comment>French</comment>. doi:<pub-id pub-id-type="doi">10.1016/j.bulcan.2018.10.009</pub-id><pub-id pub-id-type="pmid">30527816</pub-id></mixed-citation></ref><ref id="cit0030"><label>30.</label><mixed-citation publication-type="journal"><string-name><surname>Deguchi</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Shiina</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Igawa</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Kaneuchi</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Nakajima</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Dahiya</surname>
<given-names>R</given-names></string-name>. <article-title>DNA mismatch repair genes in renal cell carcinoma</article-title>. <source><italic toggle="yes">J Urol</italic></source>. <year>2003</year>;<volume>169</volume>:<fpage>2365</fpage>&#x02013;<lpage>2371</lpage>. doi:<pub-id pub-id-type="doi">10.1097/01.ju.0000065668.19267.b4</pub-id><pub-id pub-id-type="pmid">12771799</pub-id></mixed-citation></ref><ref id="cit0031"><label>31.</label><mixed-citation publication-type="journal"><string-name><surname>Stoehr</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Burger</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Stoehr</surname>
<given-names>R</given-names></string-name>, et al. <article-title>Mismatch repair proteins hMLH1 and hMSH2 are differently expressed in the three main subtypes of sporadic renal cell carcinoma</article-title>. <source><italic toggle="yes">Pathobiology</italic></source>. <year>2012</year>;<volume>79</volume>:<fpage>162</fpage>&#x02013;<lpage>168</lpage>. doi:<pub-id pub-id-type="doi">10.1159/000335642</pub-id><pub-id pub-id-type="pmid">22378480</pub-id></mixed-citation></ref><ref id="cit0032"><label>32.</label><mixed-citation publication-type="journal"><string-name><surname>Roslan</surname>
<given-names>NH</given-names></string-name>, <string-name><surname>Makpol</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Mohd Yusof</surname>
<given-names>YA</given-names></string-name>. <article-title>A review on dietary intervention in obesity associated colon cancer</article-title>. <source><italic toggle="yes">Asian Pac J Cancer Prev</italic></source>. <year>2019</year>;<volume>20</volume>:<fpage>1309</fpage>&#x02013;<lpage>1319</lpage>. doi:<pub-id pub-id-type="doi">10.31557/APJCP.2019.20.5.1309</pub-id><pub-id pub-id-type="pmid">31127882</pub-id></mixed-citation></ref></ref-list></back></article>
